These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32227023)

  • 21. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp90 regulation of fibroblast activation in pulmonary fibrosis.
    Sontake V; Wang Y; Kasam RK; Sinner D; Reddy GB; Naren AP; McCormack FX; White ES; Jegga AG; Madala SK
    JCI Insight; 2017 Feb; 2(4):e91454. PubMed ID: 28239659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.
    Wang Y; Yella JK; Ghandikota S; Cherukuri TC; Ediga HH; Madala SK; Jegga AG
    Ther Adv Respir Dis; 2020; 14():1753466620971143. PubMed ID: 33167785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
    Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
    J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophages: friend or foe in idiopathic pulmonary fibrosis?
    Zhang L; Wang Y; Wu G; Xiong W; Gu W; Wang CY
    Respir Res; 2018 Sep; 19(1):170. PubMed ID: 30189872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
    Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
    Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis.
    Hong SY; Lu YT; Chen SY; Hsu CF; Lu YC; Wang CY; Huang KL
    Cell Death Dis; 2023 Jun; 14(6):352. PubMed ID: 37291088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating IPF--all or nothing? A PRO-CON debate.
    Behr J; Kolb M; Cox G
    Respirology; 2009 Nov; 14(8):1072-81. PubMed ID: 19909457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis.
    Chang X; Xing L; Wang Y; Yang CX; He YJ; Zhou TJ; Gao XD; Li L; Hao HP; Jiang HL
    Sci Adv; 2020 May; 6(22):eaba3167. PubMed ID: 32518825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
    Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
    Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice.
    Ma PF; Gao CC; Yi J; Zhao JL; Liang SQ; Zhao Y; Ye YC; Bai J; Zheng QJ; Dou KF; Han H; Qin HY
    J Hepatol; 2017 Oct; 67(4):770-779. PubMed ID: 28596109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis.
    Sari E; He C; Margaroli C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis.
    Sun L; Fan M; Huang D; Li B; Xu R; Gao F; Chen Y
    Biomaterials; 2021 Apr; 271():120761. PubMed ID: 33774524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-Cell RNA Sequencing Provides New Insights into Therapeutic Roles of Thyroid Hormone in Idiopathic Pulmonary Fibrosis.
    Wang L; Li Z; Wan R; Pan X; Li B; Zhao H; Yang J; Zhao W; Wang S; Wang Q; Yan P; Ma C; Yuan H; Zhao M; Rosas I; Ding C; Sun B; Yu G
    Am J Respir Cell Mol Biol; 2023 Oct; 69(4):456-469. PubMed ID: 37402274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spatial targeting of fibrosis-promoting macrophages with nanoscale metal-organic frameworks for idiopathic pulmonary fibrosis therapy.
    Hou J; Cong Y; Ji J; Liu Y; Hong H; Han X
    Acta Biomater; 2024 Jan; 174():372-385. PubMed ID: 38072226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quercetin Enhances Ligand-induced Apoptosis in Senescent Idiopathic Pulmonary Fibrosis Fibroblasts and Reduces Lung Fibrosis In Vivo.
    Hohmann MS; Habiel DM; Coelho AL; Verri WA; Hogaboam CM
    Am J Respir Cell Mol Biol; 2019 Jan; 60(1):28-40. PubMed ID: 30109946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b.
    Marinari S; De Iuliis V; Dadorante V; Colella S; Marino A; Nunziata A; Flati V; Caruso M; Pennelli A; De Benedetto F; Matera S; Capodifoglio S; Martinotti S; Caputi S; Toniato E
    J Biol Regul Homeost Agents; 2017; 31(1):59-69. PubMed ID: 28337871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.